Latest news with #TorrentPharmaceuticals
Time of India
7 hours ago
- Health
- Time of India
Torrent Pharma addresses the everyday nutritional gaps in Shelcal Total's new ad
Torrent Pharmaceuticals has announced the launch of Shelcal Total , a scientifically formulated adult nutrition supplement powder that expands its flagship Shelcal brand into the rapidly growing Nutrition segment. The portfolio has since expanded with consumer-friendly innovations like Shelcal Pro Gummies and Shelcal Pro Kids Gummies, reinforcing the brand's relevance across age groups and evolving health needs. Shelcal Total now marks the brand's evolution into a modern, consumer-focused nutrition portfolio. 'India is facing a growing nutrition gap driven by lifestyle changes, poor dietary habits, and rising stress levels — all of which contribute to deficiencies across age groups,' said Amal Kelshikar chief commercial officer, India business, Torrent Pharma. 'As health awareness increases and more adults are in need of convenient holistic nutrition, the demand for trusted, convenient solutions is only accelerating. Shelcal Total is our answer to that need — a science-backed, great-tasting supplement that makes comprehensive daily nutrition more accessible and easier to adopt, while upholding Shelcal's long-standing credibility and consumer trust,' Kelshikar added. Shelcal Total is a comprehensive daily supplement combining high-quality protein, essential vitamins, minerals, and functional nutrients to support bone, muscle and joint health, energy, immunity, gut health, brain health and skin health —addressing the everyday nutritional gaps faced by modern Indian adults. Formulated with vegetarian-origin ingredients, Shelcal Total contains no added sugar, artificial colours and flavours, making it suitable for health-conscious adults managing their calorie intake. 'Through the years, I have observed that the challenge most Indian adults, particularly those over 30, face aren't just individual nutrient gaps, but how these interconnected deficiencies affect bone density, muscle mass, and joint mobility,' said Nmami Agarwal, certified nutritionist. "Shelcal Total has comprehensive approach with nutrients to address the common prevalent deficiencies, even beyond bone and joint health. For busy professionals and aging adults who struggle to meet their nutritional needs through diet alone, this is a practical, science-backed solution due to its multitude of nutrients to help fulfil required RDA,' Agarwal added. Watch the video here:
&w=3840&q=100)
Business Standard
9 hours ago
- Business
- Business Standard
Torrent Pharma bucks weak market trend; rallies 3%, hits record high
Torrent Pharma Q1FY26 results on Monday, July, 28, 2025: In past one month, the stock has outperformed by surging 12%, as compared to 1.4% decline in the Sensex and 4% rise in the BSE Healthcare index Torrent Pharma share price today Shares of Torrent Pharmaceuticals hit a record high of ₹3,612.20, as they rallied 3 per cent on the BSE in Friday's intra-day trade in an otherwise weak market. The stock price of the pharmaceutical company surpassed its previous high of ₹3,589.95 touched on October 10, 2024. In comparison, the BSE Sensex was down 0.74 per cent at 81,579 at 01:59 PM. In the past one month, Torrent Pharmaceuticals has outperformed the market by surging 12 per cent. In comparison, the BSE Sensex was down 1.4 per cent, while, BSE Healthcare index gained 4 per cent during the period. CATCH STOCK MARKET LIVE UPDATES TODAY Q1FY26 results on Monday, July, 28, 2025 The board of directors of Torrent Pharmaceuticals will meet on Monday, July 28, 2025 to consider and approve the audited financial results of the company for the quarter ended on June 30, 2025 (Q1FY26). Torrent - JB Chemicals Pharmaceuticals (JBCP) deal On June 29, 2025, Torrent Pharmaceuticals announced a major strategic move with the acquisition of a controlling 46.4 per cent stake in JB Chemicals & Pharmaceuticals (JBCP) for ₹11,920 crore at ₹1,600 per share from the promoter Tau Investment Holdings or KKR. In addition, the company launched an open offer for a further 26 per cent at ₹1,639.18 per share and intends to merge JBCP within itself through a court-approved scheme. This represents Torrent Pharma's largest-ever acquisition and positions it as a stronger firm in India's branded generics landscape, with deeper reach across therapeutic areas and geographies. Torrent's deep India presence and JBCP's fast growing India business, combined with the Contract Development and Manufacturing Organization (CDMO) and international footprint offers immense potential to scale both revenue and profitability. This strategic alignment furthers Torrent's goal of strengthening the company's presence in the Indian pharma market, and build a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent. The combined entity would operate at ₹15,400 crore revenue base with a broader branded portfolio and expanded international presence. While the acquisition premium is steep, long-term value creation hinges on efficient integration, synergy realization, and sustained growth across domestic and global businesses, according to analysts at Elara Capital. Way Forward Moving ahead, Torrent Pharma in its FY25 annual report said that the company's focus will be on consolidating and strengthening its leadership position in the branded generic segment. In India, the company will focus on strengthening its leadership in key therapy areas, expanding consumer health portfolio, and enhancing field force productivity to capture untapped opportunities. In the international markets, the company anticipates continued growth in Brazil, driven by recent successful launches and a robust pipeline awaiting regulatory approvals. In Germany, new tender wins are expected to support revenue growth despite some challenges in the OTC segment. The US market remains stable, with a focus on maintaining compliance and a strong product pipeline, the company said. India-UK Free Trade to benefit pharma companies The India-UK Free Trade Agreement is set to boost India's pharma Industry by expanding market access for generics and biosimilars, fast-tracking approvals, and encouraging cross-border R&D. It also enables collaborations in bulk drug imports and CDMO. While most pharma exports to the UK were already duty-free, the UK's commitment to zero tariffs on 99 per cent of exports formalises this, offering long-term clarity. Pharma exports to the UK stood at ~US$910 million in FY24, ICICI Securities said in a note.
Time of India
a day ago
- Health
- Time of India
Torrent launches nutrition supplement powder for adults
Mumbai: Ahmedabad-based Torrent Pharmaceuticals has launched a nutrition supplement powder for adults to boost consumer-focused nutrition portfolio. The nutritional supplement is branded as Shelcal Total , a brand name acquired by Torrent Pharma in 2013, and was used to market gummies for adults and kids. Shelcal Total is a daily supplement designed to deliver targeted nutrients including calcium, magnesium, vitamin D3 and K2 for bone strength , and has glucosamine and bamboo shoot extract for joint health, the company said in a release. As per the company, of India's total $42.97 billion (around ₹3.57 lakh crore) nutrition supplements market powdered supplements account for nearly 38 per cent of the total share and with their bioavailability and ease of daily integration the segment stands as high-growth category going forward. 'With increase in health awareness, more adults are in need of convenient holistic nutrition, the demand for trusted, convenient solutions is only accelerating,' said Amal Kelshikar Chief Commercial Officer, India Business, Torrent Pharma.
Hans India
7 days ago
- Business
- Hans India
Torrent Pharma set to be India's 2nd pharma major
New Delhi: Ahmedabad-based Torrent Pharmaceuticals has sought fair trade regulator CCI's clearance to acquire a majority stake in in JB Chemicals and Pharmaceuticals in a Rs19,500-crore the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in JB Chemicals and Pharmaceuticals in a Rs19,500-crore deal. 'The proposed combination relates to acquisition of shareholding by the acquirer (Torrent Pharmaceuticals Ltd) in the target (JB Chemicals & Pharmaceuticals Ltd) and the subsequent amalgamation of the target with the acquirer,' according to a notice filed with the Competition Commission of India (CCI). Torrent Pharmaceuticals is the flagship company of the Torrent group and is engaged in the business of manufacturing and sale of pharmaceutical formulations (FDFs) across therapeutic segments.
Business Standard
18-07-2025
- Business
- Business Standard
Torrent Pharma seeks CCI nod for ₹19,500 cr majority stake in JB Chemicals
Ahmedabad-based Torrent Pharmaceuticals has sought fair trade regulator CCI's clearance to acquire a majority stake in in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to acquisition of shareholding by the acquirer (Torrent Pharmaceuticals Ltd) in the target (J B Chemicals & Pharmaceuticals Ltd) and the subsequent amalgamation of the target with the acquirer," according to a notice filed with the Competition Commission of India (CCI). Torrent Pharmaceuticals is the flagship company of the Torrent group and is engaged in the business of manufacturing and sale of pharmaceutical formulations (FDFs) across therapeutic segments. J B Chemicals & Pharmaceuticals is engaged in business of manufacturing and marketing of diverse range of FDFs and APIs (Active Pharmaceutical Ingredients) and also provides CDMO (Contract Development and Manufacturing Organisation) services as well. The parties (Torrent Pharma and J B Chemicals) said that their activities exhibit horizontal overlaps in certain relevant markets for the manufacturing and sale of FDFs in India. In June, Torrent said it will acquire 46.39 per cent stake from promoters Tau Investment Holdings Pte Ltd, an affiliate of global investment firm KKR, for about Rs 11,917 crore. It would additionally buy another 2.80 per cent from certain employees of JB Chemicals at the same acquisition price of Rs 1,600 per share (totaling Rs 719 crore). Post this, it would make an open offer for buying 26 per cent from open market, as per listing norms, at a price of Rs 1,639.18 per share (totaling Rs 6,842.8 crore). This will be the second biggest deal in the pharma sector ever, behind Sun Pharmaceutical Industries' 2015 acquisition of Ranbaxy Laboratories. Post share purchase, JB Pharma will merge into Torrent. In 2020, KKR had bought a 65 per cent stake in JB Chemicals & Pharmaceuticals. In March this year, KKR divested a 5.8 per cent stake in JB Pharma for Rs 1,460 crore through open market transactions. Established in 1976, JB Pharma produces a range of pharmaceuticals in areas such as gastroenterology, dermatology and diabetes, etc. Torrent Pharma, with annual revenues of more than Rs 11,500 crore, is the flagship company of the Torrent Group, with group revenues of Rs 45,000 crore. In April 2014, Sun Pharma had announced it would acquire troubled rival Ranbaxy in an all-stock transaction worth USD 4 billion that includes USD 800 million debt. The merger was 'consummated' following receipt of requisite approvals a year later in March 2015. In another big deal, Mankind Pharma last year completed the transaction to acquire Bharat Serums and Vaccines for a consideration of Rs 13,768 crore.
